At the time of writing, Tourmaline Bio Inc [TRML] stock is trading at $26.23, up 2.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TRML shares have gain 11.38% over the last week, with a monthly amount glided 55.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Tourmaline Bio Inc [NASDAQ: TRML] stock has seen the most recent analyst activity on December 15, 2023, when Jefferies initiated its Buy rating and assigned the stock a price target of $41. On November 17, 2023, Truist initiated with a Buy rating and assigned a price target of $43 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $50 on October 31, 2023. Piper Sandler initiated its recommendation with a Overweight and recommended $65 as its price target on October 25, 2023. H.C. Wainwright started tracking with a Buy rating for this stock on October 20, 2022, and assigned it a price target of $18. In a note dated July 05, 2022, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $20 to $8.
For the past year, the stock price of Tourmaline Bio Inc fluctuated between $9.18 and $48.31. Currently, Wall Street analysts expect the stock to reach $65.33 within the next 12 months. Tourmaline Bio Inc [NASDAQ: TRML] shares were valued at $26.23 at the most recent close of the market. An investor can expect a potential return of 149.07% based on the average TRML price forecast.
Analyzing the TRML fundamentals
Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -19.47%, Pretax Profit Margin comes in at -15.68%, and Net Profit Margin reading is -15.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.14 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.03 points at the first support level, and at 23.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.11, and for the 2nd resistance point, it is at 28.00.
Ratios To Look Out For
It is important to note that Tourmaline Bio Inc [NASDAQ:TRML] has a current ratio of 46.87. Also, the Quick Ratio is 46.87, while the Cash Ratio stands at 11.03.
Transactions by insiders
Recent insider trading involved Kulkarni Sandeep Chidambar, CEO, that happened on Aug 21 ’24 when 1779.0 shares were purchased. CEO, Kulkarni Sandeep Chidambar completed a deal on Aug 16 ’24 to buy 5221.0 shares. Meanwhile, Director MCDADE MARK bought 100000.0 shares on Jan 29 ’24.
